Risks and side effects of islet transplantation
Abstract
Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia has been a net benefit.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Immunosuppressive drugs used for whole organ transplants can successfully retain graft viability but can have serious side-effects, including an increased risk of infection and cancer as well as less severe but uncomfortable symptoms.
“While these drugs can successfully retain graft viability, they also can have serious side-effects, including an increased risk of infection and cancer as well as less severe but uncomfortable symptoms.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [81]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 57 · Cited by 137
- Authors
- Ryan, E. A., Paty, B. W., Senior, P. A., & Shapiro, A. M. J.
- Venue
- Current Diabetes Reports
- Published
- 2004-07
- Volume
- 4
- Issue
- 4
- Pages
- 304-309
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- OpenAlex
- W2106261209
- Cited by
- 137
- References
- 57
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 5 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 10 · 2018: 6 · 2017: 3 · 2016: 5 · 2015: 2 · 2014: 5 · 2013: 7 · 2012: 8
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Diabetes Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- islet transplantation, complications, hypoglycemia, immunosuppression, portal vein thrombosis, hemorrhage, cancer, infection, diabetes complications, glycemic control, insulin independence
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Immunosuppressive Agents, Postoperative Complications, Risk Factors, Islets of Langerhans Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
